Efficacy of Amiodarone for the Termination of Chronic Atrial Fibrillation and Maintenance of Normal Sinus Rhythm: A Prospective, Multicenter, Randomized, Controlled, Double Blind Trial

Author:

Galperin Jorge1,Elizari Marcelo V.,Chiale Pablo A.,Molina Remberto Torres2,Ledesma Rauil3,Scapin Angel O.4,Blanco Manuel Vaizquez5

Affiliation:

1. GEFACA Investigators-GEMA GROUP, Buenos Aires, Argentina; Hospital Durand, Buenos Aires, Argentina

2. GEFACA Investigators-GEMA GROUP, Buenos Aires, Argentina; Hospital Ramos Mejia, Buenos Aires, Argentina

3. GEFACA Investigators-GEMA GROUP, Buenos Aires, Argentina; Instituto del Corazon, Cordoba, Argentina

4. GEFACA Investigators-GEMA GROUP, Buenos Aires, Argentina; G.E.M.A. Grupo de Estudios Multicentricos Argentinos, Argentina

5. GEFACA Investigators-GEMA GROUP, Buenos Aires, Argentina; Hospital de Clinicas, Buenos Aires, Argentina

Abstract

Objective: We sought to assess the efficacy and safety of amiodarone for restoration and maintenance of sinus rhythm in patients with chronic atrial fibrillation in a prospective, randomized, double blind trial. Background: Restoration and preservation of sinus rhythm is difficult in patients with chronic atrial fibrillation. The efficacy of oral amiodarone has not been conclusively established. Methods: Ninety-five patients with chronic atrial fibrillation, lasting an average of 35.6 months, were randomized to either amiodarone (600 mg/d) (47 patients) or placebo (48 patients) during four weeks. Nonresponders underwent electric cardioversion, and those who reverted continued with amiodarone (200 mg/d) or placebo. End-points were successful cardioversion and sinus rhythm maintenance. Results: Sixteen patients (34.04%) in the amiodarone group reverted within 27.28 ± 8.85 days in comparison with 0% in the placebo group (P < 0.000009). The conversion rate rose to 51.72% in patients with chronic atrial fibrillation lasting less than 12 months. Twenty-eight patients in the amiodarone group and 39 in the placebo group underwent electric cardioversion, which was successful in 19 patients (67.8%) of the amiodarone group and in 15 (38.46%) of the placebo group (P = 0.017). Altogether, conversion was obtained in 79.54% of the amiodarone group patients and in 38.46% of the placebo group patients (P < 0.0001). During follow-up, atrial fibrillation relapsed in 13 (37.14%) of 35 patients of the amiodarone group within 8.84 + 8.57 months and in 12 (80%; P = 0.009) of 15 patients of the placebo group within 2.74 ± 3.41 months. Conclusions: Oral amiodarone restored sinus rhythm in one third of patients with chronic atrial fibrillation, increased the success rate of electric cardioversion, decreased the number of relapses and delayed their occurrence.

Publisher

SAGE Publications

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine,Pharmacology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3